Electro-Optical Sciences, Inc. ("EOS") (NASDAQ: MELA) announced that patient accrual in the MelaFind® pivotal trial was completed last week. MelaFind is a non-invasive, point-of-care instrument designed and developed by EOS to assist in the early diagnosis of melanoma, the deadliest form of skin cancer. "This represents a significant milestone for the company in our quest to improve early melanoma detection," said Joseph V. Gulfo, MD, MBA, President & CEO.
This post is an original post by ScienceDaily: Skin Care News
